Immunovant

Reorganization team change restructure
Biotech

Immunovant narrows R&D focus as Roivant execs join C-suite

Having once eyed 10 indications, Immunovant has narrowed its focus to six settings where it could start delivering registrational data in 2027.
Nick Paul Taylor Apr 21, 2025 10:00am
relay

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am
long distance runners race ultramarathon marathon

Immunovant promotes next-gen FcRn drug in race to rival Vyvgart

May 30, 2024 7:02am
light idea burst ruin destroy lightning shot

JPM24: Roivant CEO has ‘pangs of regret’ for letting Telavant go

Jan 12, 2024 10:30am
An arrow incrementally going up stairs before pointing straight up Blue background

Immunovant posts midphase FcRn data in Graves’, plots next steps

Dec 21, 2023 7:00am
graphic image of a cube with an arrow nailing the bullseye

Roivant FcRn inhibitor avoids cholesterol problem, shares spike

Sep 26, 2023 10:56am